These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 23727419

  • 1. Clinical evaluation of transcatheter arterial chemoembolization with 2-day-soluble gelatin sponge particles for hepatocellular carcinoma-comparison with insoluble gelatin sponge particles.
    Kawai N, Sato M, Minamiguchi H, Ikoma A, Sanda H, Nakata K, Sato H, Sakaguchi H, Nakai M, Sonomura T.
    J Vasc Interv Radiol; 2013 Sep; 24(9):1383-90. PubMed ID: 23727419
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents.
    Chen S, Yu W, Zhang K, Liu W, Chen Q.
    Medicine (Baltimore); 2018 May; 97(21):e10832. PubMed ID: 29794774
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents.
    Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, Crippin JS.
    J Vasc Interv Radiol; 2005 Dec; 16(12):1661-6. PubMed ID: 16371533
    [Abstract] [Full Text] [Related]

  • 6. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).
    Iezzi R, Cesario V, Siciliani L, Campanale M, De Gaetano AM, Siciliano M, Agnes S, Giuliante F, Grieco A, Pompili M, Rapaccini GL, Gasbarrini A, Bonomo L, HepatoCATT Group for the Multidisciplinary Management of HCC.
    Radiol Med; 2013 Jun; 118(4):555-69. PubMed ID: 23358819
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy.
    Zhao GS, Li C, Liu Y, Ren ZZ, Yuan XL, Zhou J, Zhang YW, Zhang M.
    Medicine (Baltimore); 2017 Apr; 96(16):e6629. PubMed ID: 28422858
    [Abstract] [Full Text] [Related]

  • 12. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S, Kim KM, Lee SJ, Lee KH, Lee DY, Kim MD, Kim DY, Kim SU, Won JY.
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Matsumoto T, Ichikawa H, Imai J, Hayashi T, Tomita K, Mine T, Kojima S, Watanabe N, Hasebe T.
    Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
    [Abstract] [Full Text] [Related]

  • 15. A new soluble gelatin sponge for transcatheter hepatic arterial embolization.
    Takasaka I, Kawai N, Sato M, Sahara S, Minamiguchi H, Nakai M, Ikoma A, Nakata K, Sonomura T.
    Cardiovasc Intervent Radiol; 2010 Dec; 33(6):1198-204. PubMed ID: 20431885
    [Abstract] [Full Text] [Related]

  • 16. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, Ou MC.
    BMC Gastroenterol; 2018 Aug 03; 18(1):124. PubMed ID: 30075752
    [Abstract] [Full Text] [Related]

  • 17. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study.
    Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, Balzano S, Florio F.
    Radiology; 2000 Apr 03; 215(1):123-8. PubMed ID: 10751477
    [Abstract] [Full Text] [Related]

  • 18. Chemoembolization for hepatocellular carcinoma: epinephrine followed by a doxorubicin-ethiodized oil emulsion and gelatin sponge powder.
    Clouse ME, Stokes KR, Kruskal JB, Perry LJ, Stuart KE, Nasser IA.
    J Vasc Interv Radiol; 1993 Apr 03; 4(6):717-25. PubMed ID: 7506597
    [Abstract] [Full Text] [Related]

  • 19. Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma.
    Yang L, Zhang XM, Tan BX, Liu M, Dong GL, Zhai ZH.
    J Comput Assist Tomogr; 2012 Apr 03; 36(2):226-30. PubMed ID: 22446364
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma.
    Takaki S, Sakaguchi H, Anai H, Tanaka T, Yamamoto K, Morimoto K, Nishiofuku H, Inoue M, Sueyoshi S, Nagata T, Hidaka T, Uchida H, Kichikawa K.
    Cardiovasc Intervent Radiol; 2012 Jun 03; 35(3):544-54. PubMed ID: 21739345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.